Clinical Trials Sponsored by Merck Serono S.A.S, France

Total 12 results

Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France (ECOS FRA)

Growth Disorders

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (ATTAC-PCO)

Polycystic Ovarian Syndrome

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Hypochondroplasia

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin) (SEPAGE)

Infant, Small for Gestational Age

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Terminated

EXpression PRofile Endometrium Samples Study (EXPRESS)

In Vitro Fertilization

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Multiple Sclerosis, Relapsing, Remitting
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany

Completed

Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age (SGA OPTIMIS)

Small Gestational Age (SGA)
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
French Cardiology Society
Merck Serono International SA

Completed

Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome (EVANACS)

Acute Coronary Syndrome (ACS)

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; Merck Serono International SA; Ligue contre...

Completed

Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer (ELAN-UNFIT)

Head Neck Cancer Squamous Cell Recurrent

France
Collège National des Généralistes Enseignants
Assistance Publique - Hôpitaux de Paris; Institut National de la Santé Et de... and other collaborators

Completed

Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice (ESCAPE)

High Risk Hypertensive Patients

France

Clinical Trials Sponsored by Merck Serono S.A.S, France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations